The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression
Open accessAbstract
The development of cancer-specific therapeutics has been limited because most healthy cells and cancer cells depend on common pathways. Pyruvate kinase (PK) exists in M1 (PKM1) and M2 (PKM2) isoforms. PKM2, whose expression in cancer cells results in aerobic glycolysis and is suggested to bestow a selective growth advantage, is a promising target. Because many oncogenes impart a common alteration in cell metabolism, inhibition of the M2 isoform might be of broad applicability. We show that several small interfering (si) RNAs designed to target mismatches between the M2 and M1 isoforms confer specific knockdown of the former, resulting in decreased viability and increased apoptosis in multiple cancer cell lines but less so in normal fibroblasts or endothelial cells. In vivo delivery of siPKM2 additionally causes substantial tumor regression of established xenografts. Our results suggest that the inherent nucleotide-level specificity of siRNA can be harnessed to develop therapeutics that target isoform-specific exons in genes exhibiting differential splicing patterns in various cell types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Known as the Warburg effect (Warburg 1956), this reprogramming of gene expression that alters glucose metabolism enables cells to suppress apoptotic signaling, to grow in hypoxic environments, and to use more glucose for anabolic processes rather than oxidative phosphorylation, even when oxygen is…”
BackgroundAlternative isoform regulation in human tissue transcriptomes
Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Mazurek, S. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.005 · Cited by 694
Clower, C. V., Chatterjee, D., Wang, Z., Cantley, L. C., Vander Heiden, M. G., & Krainer, A. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914845107 · Cited by 424 · cited 2×
“Pyruvate kinase activity can be modulated not only by alternative splicing (Clower et al., 2010; David et al., 2010) but also by allostery (Boxer et al., 2010; Vander Heiden et al., 2010a).”
BackgroundAshizawa, K., Willingham, M. C., Liang, C. M., & Cheng, S. Y. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55378-3 · Cited by 172
Cited by
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.025 · Cited by 549
“Knockdown of PKM2 in xenograft tumors has yielded contradictory results regarding the requirement for PKM2 in tumor growth (CortésCros et al., 2013; Goldberg and Sharp, 2012), further highlighting the need to investigate the role of PKM2 in the context of spontaneous tumors arising in situ.”
InfluentialPyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
Zahra, K., Dey, T., Ashish, Mishra, S. P., & Pandey, U. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00159 · Cited by 501
Emerging roles of PKM2 in cell metabolism and cancer progression
Luo, W., & Semenza, G. L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.010 · Cited by 376
Targeting glucose metabolism for cancer therapy
Hamanaka, R. B., & Chandel, N. S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120162 · Cited by 369
Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2
Liang, J., Cao, R., Wang, X., Zhang, Y., Wang, P., Gao, H., Li, C., Yang, F., Zeng, R., Wei, P., et al. (2017) · Cell Research · doi:10.1038/cr.2016.159 · Cited by 350
Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis
Wang, Y.-H., Israelsen, W. J., Lee, D., Yu, V. W. C., Jeanson, N. T., Clish, C. B., Cantley, L. C., Vander Heiden, M. G., & Scadden, D. T. (2014) · Cell · doi:10.1016/j.cell.2014.07.048 · Cited by 348
PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation
Azoitei, N., Becher, A., Steinestel, K., Rouhi, A., Diepold, K., Genze, F., Simmet, T., & Seufferlein, T. (2016) · Molecular Cancer · doi:10.1186/s12943-015-0490-2 · Cited by 336
PKM2 and cancer: The function of PKM2 beyond glycolysis
DONG, G., MAO, Q., XIA, W., XU, Y., WANG, J., XU, L., & JIANG, F. (2016) · Oncology Letters · doi:10.3892/ol.2016.4168 · Cited by 325
Masson, N., & Ratcliffe, P. J. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-3 · Cited by 298
Lim, S.-O., Li, C.-W., Xia, W., Lee, H.-H., Chang, S.-S., Shen, J., Hsu, J. L., Raftery, D., Djukovic, D., Gu, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2478 · Cited by 266
Synergistic nanomedicine by combined gene and photothermal therapy
Kim, J., Kim, J., Jeong, C., & Kim, W. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.018 · Cited by 262
Caruso, P., Dunmore, B. J., Schlosser, K., Schoors, S., Dos Santos, C., Perez-Iratxeta, C., Lavoie, J. R., Zhang, H., Long, L., Flockton, A. R., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028034 · Cited by 258
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
“In vivo, siPKM2 delivery caused regression of established xenografts (42).”
BackgroundThe metabolic landscape of lung cancer: New insights in a disturbed glucose metabolism
Vanhove, K., Graulus, G.-J., Mesotten, L., Thomeer, M., Derveaux, E., Noben, J.-P., Guedens, W., & Adriaensens, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01215 · Cited by 147
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention
Zhang, Y., & Yang, J.-M. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22958 · Cited by 132
Coordinating Bacterial Cell Division with Nutrient Availability: a Role for Glycolysis
Monahan, L. G., Hajduk, I. V., Blaber, S. P., Charles, I. G., & Harry, E. J. (2014) · mBio · doi:10.1128/mbio.00935-14 · Cited by 123
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma
Zhang, S., Wei, J. S., Li, S. Q., Badgett, T. C., Song, Y. K., Agarwal, S., Coarfa, C., Tolman, C., Hurd, L., Liao, H., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.11.045 · Cited by 58
Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies
Robert, G., Jacquel, A., & Auberger, P. (2019) · Cells · doi:10.3390/cells8101260 · Cited by 45
Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads
Wang, J., Zhou, S., Cheng, Y., Cheng, L., Qin, Y., Zhang, Z., Bi, A., Xiang, H., He, X., Tian, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01563 · Cited by 18
Metadata
- Authors
- Goldberg, M. S., & Sharp, P. A.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-01-23
- Volume
- 209
- Issue
- 2
- Pages
- 217-224
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2142748510
- Cited by
- 230
- References
- 9
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.